Leadership And ExpertiseJade Biosciences is led by a world-class team that previously sold its IgAN portfolio to Novartis for a substantial amount, indicating strong leadership and expertise.
Market PotentialJADE-001 is projected to become the optimal disease-modifying therapy for IgAN and could capture a significant share of a large market.
Therapeutic AdvantageJADE-001 is an anti-APRIL mAb with significantly greater potency and a longer dosing interval, offering an optimal benefit-risk profile for chronic therapy.